A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT Vs. AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer
Principal Investigator
Howard Sandler, MD MS
Status
Terminated
Date of Study Termination
May 20 2022
Disease Site
Genitourinary [GU]
Prostate
Phase
III
Developmental Therapeutics
No
Primary Objective
Patient Population
-
Target Accrual
600
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.